Bionano Genomics, Inc. revised revenue guidance for the third quarter ended September 30, 2023. Revenues for the third quarter of 2023 are expected to be in the range of $9.1 million to $9.3 million, an estimated increase of 26% to 29% compared to the third quarter of 2022, which would be at the higher end of revenue guidance of $8.8 million to $9.2 million provided in August 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7861 USD | +3.57% | +4.81% | -58.41% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.41% | 48.13M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B | |
+26.76% | 32.03B |
- Stock Market
- Equities
- BNGO Stock
- News Bionano Genomics, Inc.
- Bionano Genomics, Inc. Revises Revenue Guidance for the Third Quarter Ended September 30, 2023